Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 6,859 shares, a decline of 33.8% from the June 30th total of 10,359 shares. Based on an average trading volume of 6,436 shares, the short-interest ratio is currently 1.1 days.
Defence Therapeutics Stock Up 6.3%
OTCMKTS DTCFF opened at $0.30 on Friday. The stock’s 50-day moving average is $0.34 and its 200-day moving average is $0.39. Defence Therapeutics has a one year low of $0.25 and a one year high of $0.78.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Further Reading
- Five stocks we like better than Defence Therapeutics
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
- MarketBeat Week in Review – 07/27- 07/31
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
